OmniAb, Inc. (NASDAQ:OABIW)
| Market Cap | 1.37B+81.9% |
| Revenue (ttm) | 38.43M+66.9% |
| Net Income | -44.26M+30.3% |
| EPS | -0.36+40.0% |
| Shares Out | 144.97M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 33 |
| Open | 0.22 |
| Previous Close | 0.37 |
| Day's Range | 0.22 - 0.22 |
| 52-Week Range | 0.17 - 0.37 |
| Beta | 1.22 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 17, 2026 |
No insider has filed an open-market purchase or sale here in the last 90 days, so there is nothing to score yet.
About OABIW
OmniAb, Inc., established in 2012 and headquartered in Emeryville, California, operates as a biotechnology firm focused on pioneering technologies for the discovery of therapeutic antibodies within the United States. The company's flagship offering is its OmniAb platform, which provides industry collaborators with access to a broad spectrum of antibody repertoires and advanced screening techniques. This capability empowers partners to develop next-generation therapeutic agents. At the heart of the OmniAb platform are proprietary transgenic animals, including OmniRat, OmniChicken, and OmniMouse. These animals have been genetically engineered to produce antibodies featuring human sequences, thereby streamlining the path to creating human therapeutic candidates. Beyond this core offering, OmniAb also addresses specific industry needs with specialized animal models: OmniFlic (a transgenic rat) and OmniClic (a transgenic chicken) facilitate bispecific antibody applications through a shared light chain mechanism. Additionally, OmniTaur provides a solution for challenging targets by leveraging the distinctive structural characteristics of cow antibodies.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$OABIW stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in OABIW holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by OABIW's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
OABIW Estimated quarterly lobbying spending
Source: U.S. Senate LDA
OABIW Revenue by Segment
| Segment | Revenue | % of All |
|---|---|---|
| xPloration revenue | $1.16M | 65.56% |
| Cost of xPloration revenue | $610.00K | 34.44% |
As of: Q2 2026 (Jun 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New OABIW patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to OABIW from public contracts
Source: USAspending.gov
OABIW Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from OABIW’s recent data — informational, not investment advice